ABMD - アビオメド （ABIOMED Inc.） アビオメドABMDのチャート
ABMDの企業情報
| symbol | ABMD |
|---|---|
| 会社名 | ABIOMED Inc. （アビオメド） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 アビオメッド(Abiomed Inc.)は機械的循環補助装置のプロバイダーであり、心不全患者向けに連続介護を提供する。同社は血流を改善、または心臓ポンプ機能を果たすことによって心臓を休息、治癒、回復させるように設計された製品を開発･製造･販売する。同社の製品は心臓カテーテル検査室で介入治療を行う心臓専門医に利用され、また心臓外科医が行う心臓手術スイートで血管形成術或は心臓外科手術前･中･後、予防的･緊急的に血行力学的補助を必要とする患者を対象に利用されている。平成24年9月、同社は最大6時間の局部的循環補助を提供する製品「Impella CP」が米国食品医薬品局（FDA）から510（k）認可を取得したと発表した。 アビオメドは、米国の医療装置メ―カ―。心不全患者の心臓回復治療に必要な循環補助装置や内蔵型循環補助装置、モニタリング装置を開発、製造、販売する。また、小型心臓ポンプや完全人工心臓の開発を手掛ける。米国内だけでなく、世界各国で製品の販売を行う。本社はマサチュ―セッツ州ダンバ―ス。 Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function. |
| 本社所在地 | 22 Cherry Hill Drive Danvers MA 01923 USA |
| 代表者氏名 | Michael R. Minogue マイケル・R・ミノーグ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 978-777-5410 |
| 設立年月日 | 29799 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 1143人 |
| url | www.abiomed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/abmd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 182.30800 |
| 終値（lastsale） | 399.16 |
| 時価総額（marketcap） | 17913167185.6 |
| 時価総額 | 時価総額（百万ドル） 17730.07 |
| 売上高 | 売上高（百万ドル） 641.29100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 17369.554 |
| 当期純利益 | 当期純利益（百万ドル） 186.26200 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 30 June 2018 ABIOMED Inc. revenues increased 36% to $180M. Net income increased from $37.4M to $90.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Investment income net increase from $635K to $1.6M (income) Other income (expense) net) increase from $79K to $188K (income). |
ABMDのテクニカル分析
ABMDのニュース
Abiomed''s Impella RP Flex gets FDA approval to treat right heart failure 2022/10/31 13:44:37 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) granted pre-market approval ((PMA)) to Abiomed''s (ABMD) Impella RP Flex with SmartAssist to treat acute right heart failure for up to…
Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure 2022/10/31 12:02:00 Wallstreet:Online
Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the internal jugular (IJ) vein, which enables patient mobility, and has dual-sensor technology designed
Abiomed completes post-approval reports for FDA for Impella heart pumps 2022/10/20 14:48:18 Seeking Alpha
The US FDA has accepted Abiomeds (ABMD) post-approval study reports related to the pre-market approvals for its Impella heart pumps.
Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure 2022/10/20 14:24:00 Wallstreet:Online
Abiomed (Nasdaq: ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The FDA’s action is another affirmation that Impella heart pumps are safe and effective for cardiogenic shock, high-risk PCI, post-cardiotomy cardiogenic shock, cardiogenic shock in the setting of
U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath 2022/10/17 11:58:00 Wallstreet:Online
The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed (Nasdaq: ABMD) for its Impella Low Profile Sheath. Compared to the existing 14 French (Fr) sheath used for placement of Impella CP, the new sheath maintains the same inner diameter, but reduces the outer diameter by nearly 2 Fr. As a result of its smaller size and other technological advancements, the Low
Why Shares of Abiomed Rose 18.4% in July 2022/08/08 19:21:00 The Motley Fool
The company''s stock rose steadily throughout the month.
ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript 2022/08/05 12:13:13 AlphaStreet
ABIOMED, Inc. (NASDAQ: ABMD) Q1 2023 earnings call dated Aug. 04, 2022 Corporate Participants: Nicole Nath — Manager of Investor Relations Michael R. Minogue — Chairman, Chief Executive Officer and President Todd A. Trapp — Executive […] The post ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript first appeared on AlphaStreet .
ABIOMED, Inc. (ABMD) Q1 2023 Earnings Call Transcript | AlphaStreet 2022/08/05 12:13:13 AlphaStreet
ABIOMED, Inc. (NASDAQ: ABMD) Q1 2023 earnings call dated Aug. 04, 2022
Abiomed, Inc. (ABMD) CEO Mike Minogue on Q1 2023 Results - Earnings Call Transcript 2022/08/04 18:55:23 Seeking Alpha
Abiomed, Inc. (NASDAQ:NASDAQ:ABMD) Q1 2023 Results Conference Call August 4, 2022 08:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and…
Abiomed shares fall as med tech lowers 2022 revenue guidance (NASDAQ:ABMD) 2022/08/04 18:31:41 Seeking Alpha
Abiomed (ABMD) is down 4% in Thursday afternoon trading after the medical technology company lowered its full-year revenue guidance due to impacts from foreign exchange rates.
Earnings Scheduled For April 28, 2022 2022/04/28 08:50:40 Benzinga
Companies Reporting Before The Bell • PBF Energy (NYSE: PBF ) is projected to report quarterly earnings at $0.26 per share on revenue of $8.24 billion. • Merck & Co (NYSE: MRK ) is estimated to report quarterly earnings at $1.83 per share on revenue of $14.68 billion. • Smith & Nephew (NYSE: SNN ) is estimated to report earnings for its first quarter. • Domino''s Pizza (NYSE: DPZ ) is estimated to report quarterly earnings at $3.05 per share on revenue of $1.03 billion. • Limelight Networks (NASDAQ: LLNW ) is projected to report quarterly loss at $0.04 per share on revenue of $56.30 million. • FTI Consulting (NYSE: FCN ) is expected to report quarterly earnings at $1.33 per share on revenue of $703.00 million. • T. Rowe Price Gr (NASDAQ: TROW ) is expected to report quarterly earnings at $2.74 per share on revenue of $1.89 billion. • Stericycle (NASDAQ: SRCL ) is likely to report quarterly earnings at $0.46 per share on revenue of $671.00 million. • Abiomed (NASDAQ: ABMD ) is estimated to report quarterly earnings at $1.
ABMD, ATRC stocks draw bullish views at Piper on proposed Medicare rates (NASDAQ:ABMD) 2022/04/19 18:55:51 Seeking Alpha
Abiomed (ABMD) and AtriCure (ATRC) were among some of the healthcare equipment makers to earn bullish views at Piper Sandler after the Centers for Medicare and Medicaid Services…
Medical-Device Stocks Surge Most Since 2020 After J&J Results - BNN Bloomberg 2022/04/19 16:51:34 BNN Bloomberg
Shares of Intuitive Surgical Inc., Abiomed Inc. and other medical-device makers rallied Tuesday after Johnson & Johnson reported stronger-than-expected sales from that division of the company.
Is Abiomed (ABMD) A Great Investment to Take? 2022/03/07 14:10:42 Insider Monkey
Harding Loevner, an investment management firm, published its “Global Small Companies Equity Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference | MarketScreener 2022/02/08 21:07:03 MarketScreener
Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at… | February 8, 2022